Header
For Healthcare Professionals

Despite current therapies, patients with heart failure continue to be frequently rehospitalised1,2

group-3@3x[1].jpg

  1. Njoroge JN, Teerlink JR. Pathophysiology and therapeutic approaches to acute decompensated heart failure. Circ Res. 2021;128(10):1468-1486. doi:10.1161/CIRCRESAHA.121.318186

  2. Desai AS, Stevenson LW. Rehospitalization for heart failure: predict or prevent? Circulation. 2012;126(4):501-506. doi:10.1161/CIRCULATIONAHA.112.125435

  3. Bradley EH, Curry L, Horwitz LI, et al. Hospital strategies associated with 30-day readmission rates for patients with heart failure. Circ Cardiovasc Qual Outcomes. 2013;6(4):444-450. doi:10.1161/CIRCOUTCOMES.111.000101

  4. Bergethon KE, Ju C, DeVore AD, et al. Trends in 30-day readmission rates for patients hospitalized with heart failure: findings from the Get With The Guidelines-Heart Failure Registry. Circ Heart Fail. 2016;9(6):10.1161/CIRCHEARTFAILURE/115.002594. e002594 doi:10.1161/CIRCHEARTFAILURE.115.002594

  5. Khan MS, Sreenivasan J, Lateef N, et al. Trends in 30- and 90-day readmission rates for heart failure. Circ Heart Fail. 2021;14(4):e008335. doi:10.1161/CIRCHEARTFAILURE.121.008335

  6. Lawson C, Crothers H, Remsing S, et al. Trends in 30-day readmissions following hospitalisation for heart failure by sex, socioeconomic status and ethnicity. EClinicalMedicine 2021;38:101008. doi:10.1016/j.eclinm.2021.101008

  7. Ziaeian B, Fonarow GC. The prevention of hospital readmissions in heart failure. Prog Cardiovasc Dis. 2016;58(4):379-385. doi:10.1016/j.pcad.2015.09.004

  8. Sepehrvand N, Savu A, Spertus JA, et al; Alberta HEART Investigators. Change of health related quality of life over time and its association with patient outcomes in patients with heart failure. J Am Heart Assoc. 2020(17):e017278. doi:10.1161/JAHA.120.017278

  9. Voors AA, Angermann CE, Teerlink JR, et al; The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568-574. doi:10.1038/s41591-021-01659-1

Guideline-based medical treatment at discharge, and 90-day mortality Trivandrum heart failure registry1

group-3@3x[1].jpg

  1. Harikrishnan S, Sanjay G, Anees T, Viswanathan S, Vijayaraghavan G, Bahuleyan CG, Sreedharan M, Biju R, Nair T, Suresh K, Rao AC, Dalus D, Huffman MD, Jeemon P; Trivandrum Heart Failure Registry. Clinical presentation, management, in-hospital and 90-day outcomes of heart failure patients in Trivandrum, Kerala, India: the Trivandrum Heart Failure Registry. Eur J Heart Fail. 2015 Aug;17(8):794-800.

  • CI=confidence interval; HF=heart failure.

Guideline recommendations for maintenance or optimization of GDMT during hospitalisation and pre-discharge1,2

group-3@3x[1].jpg

  1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726.

  2. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):e263-e421.

  • ACC=American College of Cardiology; AHA=American Heart Association; ESC=European Society of Cardiology; GDMT=guideline directed medical therapy; HF=heart failure; HFrEF=heart failure with reduced ejection fraction; HFSA=Heart Failure Society of America.

In the treatment of patients with HFrEF and HFpEF*

JARDIANCE is the 1st medicine clinically proven† and approved across the LVEF spectrum and treatment settings1-3

In hospital initiation‡

01-elements-placeholder-card-1-1@3x[1].jpg
01-elements-placeholder-card-1-1-copy@3x[1].jpg
01-elements-placeholder-card-1-1-copy-2@3x[1].jpg

† Proven=meeting the primary endpoint in clinical trials and being published in a peer reviewed journal.

‡ After stabilisation.

  1. Anker SD, Butler J, Filippatos G, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038 (EMPEROR-Preserved results and the publication’s Supplementary Appendix.)

  2. Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190 (EMPEROR-Reduced results and the publication’s Supplementary Appendix.)

  3. Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568-574. doi:10.1038/s41591-021-01659-1

  • *
    Adult patients with chronic heart failure (NYHA class II, III, or IV) and reduced ejection fraction (LVEF ≤ 40%).
    Adult patients with chronic heart failure (NYHA class II, III, or IV) and preserved ejection fraction (LVEF > 40%).1,2
  • §
    In the EMPEROR-Reduced trial, a randomized, double blind, parallel-group, placebo-controlled study of 3730 patients with HFrEF, the efficacy and safety of JARDIANCE 10 mg (n=1863) were evaluated vs placebo (n=1867). The primary endpoint in the EMPEROR-Reduced trial was a composite of CV death or HHF, analyzed as time to the first event. Patients treated with JARDIANCE experienced a 25% RRR in this endpoint (HR=0.75; 95% CI: 0.65, 0.86; p<0.001).2
  • ||
    In the EMPEROR-Preserved trial, a randomized, double-blind, parallel-group, placebo-controlled study of 5988 patients with HFpEF, the efficacy and safety of JARDIANCE 10 mg (n=2997) were evaluated vs placebo (n=2991). The primary endpoint in the EMPEROR-Preserved trial was a composite of CV death or HHF, analyzed as time to the first event. Patients treated with JARDIANCE experienced a 21% RRR in this endpoint (HR=0.79; 95% CI: 0.69, 0.90; p<0.001).1
  • In the EMPULSE trial, a randomized, double-blind, placebo-controlled study of 530 patients with chronic heart failure regardless of LVEF, the efficacy and safety of JARDIANCE 10 mg (n=265) were evaluated vs placebo (n=265). The primary endpoint in the EMPULSE trial was clinical benefit, defined as a hierarchical composite of death from any cause, number of heart failure events and time to first heart failure event, or a 5-point or greater difference in change from baseline in the KCCQ-TSS at 90 days, as assessed using a win ratio. Patients treated with JARDIANCE experienced an overall clinical benefit 36% more likely than with placebo (win ratio 1.36; 95% CI: 1.09, 1.68; p=0.0054).3
  • CI=confidence interval; CV=cardiovascular; HFpEF=heart failure with preserved ejection fraction; HFrEF=heart failure with reduced ejection fraction; HHF=hospitalisation for heart failure; HR=hazard ratio; KCCQ-TSS=Kansas City Cardiomyopathy Questionnaire Total Symptom Score; LVEF=left ventricular ejection fraction; NYHA=New York Heart Association; RRR=relative risk reduction.

In the treatment of hospitalised patients with HFrEF and HFpEF after stabilisation*

JARDIANCE is the 1st medicine with demonstrated efficacy and safety across the LVEF spectrum when initiated in hospital1-4

group-3@3x[1].jpg

  1. Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568-574. doi:10.1038/s41591-021-01659-1

  2. Velazquez EJ, Morrow DA, DeVore AD, et al; PIONEER-HF Investigators. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380(6):539-548. doi:10.1056/NEJMoa1812851

  3. Bhatt DL, Szarek M, Steg PG, et al; SOLOIST-WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117-128. doi:10.1056/NEJMoa2030183

  4. Teerlink JR, Diaz R, Felker GM, et al; GALACTIC-HF Investigators. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med. 2021;384(2):105-116. doi:10.1056/NEJMoa2025797

  5. Anker SD, Butler J, Filippatos G, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038 (EMPEROR-Preserved results and the publication’s Supplementary Appendix.)

  6. Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190 (EMPEROR Reduced results and the publication’s Supplementary Appendix.)

  • *
    Adult patients with chronic heart failure (NYHA class II, III, or IV) and reduced ejection fraction (LVEF ≤ 40%). 
    Adult patients with chronic heart failure (NYHA class II, III, or IV) and preserved ejection fraction (LVEF > 40%).5,6
  • CI=confidence interval; HF=heart failure; HFpEF=heart failure with preserved ejection fraction; HFrEF=heart failure with reduced ejection fraction; KCCQ-TSS=Kansas City Cardiomyopathy Questionnaire Total Symptom Score; LVEF=left ventricular ejection fraction; NYHA=New York Heart Association.

EMPULSE supports initiation of JARDIANCE in hospitalised patients*1

group-3@3x[1].jpg

  1. Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568-574. doi:10.1038/s41591-021-01659-1

  • *
    In the EMPULSE trial, a randomized, double-blind, placebo-controlled study of 530 patients with chronic heart failure regardless of LVEF, the efficacy and safety of JARDIANCE 10 mg (n=265) were evaluated vs placebo (n=265). The primary endpoint in the EMPULSE trial was clinical benefit, defined as a hierarchical composite of death from any cause, number of heart failure events and time to first heart failure event, or a 5 point or greater difference in change from baseline in the KCCQ-TSS at 90 days, as assessed using a win ratio. Patients treated with JARDIANCE experienced an overall clinical benefit 36% more likely than with placebo (win ratio 1.36; 95% CI: 1.09, 1.68; p=0.0054).1
  • ACEI=angiotensin-converting enzyme inhibitor; ARB=angiotensin II receptor blocker; ARNI=angiotensin receptor neprilysin inhibitor; CHF=chronic heart failure; CI=confidence interval; HF=heart failure; HHF=hospitalization for heart failure; IV=intravenous; KCCQ-TSS=Kansas City Cardiomyopathy Questionnaire Total Symptom Score; LVEF=left ventricular ejection fraction; MRA=mineralocorticoid receptor antagonist; T2D=type 2 diabetes.

JARDIANCE® initiation at hospital-discharge in stable HF, Results in 36% greater likelihood of clinical benefit* (EMPULSE study)1

group-3@3x[1].jpg

  1. Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568-574.

  • CI=confidence interval; DM=diabetes mellitus; HF=heart failure; HHF=hypertensive heart failure; KCCQ-TSS= kansas city cardiomyopathy questionnaire total symptom score; LVEF=left ventricular ejection fraction; T2DM=type 2 diabetes mellitus.

In the treatment of hospitalised patients with HFrEF and HFpEF after stabilisation*

JARDIANCE is the 1st HF medicine with proven† clinical benefit consistent across subgroups when initiated in hospital1

group-3@3x[1].jpg

  1. Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568-574. doi:10.1038/s41591-021-01659-1

  2. Anker SD, Butler J, Filippatos G, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038 (EMPEROR-Preserved results and the publication’s Supplementary Appendix.)

  3. Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190 (EMPEROR-Reduced results and the publication’s Supplementary Appendix.)

  • *
    Adult patients with chronic heart failure (NYHA class II, III, or IV) and reduced ejection fraction (LVEF ≤ 40%). 
    Adult patients with chronic heart failure (NYHA class II, III, or IV) and preserved ejection fraction (LVEF > 40%).2,3
  • ‡
    In the EMPULSE trial, a randomised, double-blind, placebo-controlled study of 530 patients with chronic heart failure regardless of LVEF, the efficacy and safety of JARDIANCE 10 mg (n=265) were evaluated vs placebo (n=265). The primary endpoint in the EMPULSE trial was clinical benefit, defined as a hierarchical composite of death from any cause, number of heart failure events and time to first heart failure event, or a 5-point or greater difference in change from baseline in the KCCQ-TSS at 90 days, as ass essed using a win ratio. Patients treated with JARDIANCE experienced an overall clinical benefit 36% more likely than with placebo (win ratio 1.36; 95% CI: 1.09, 1.68; p=0.0054).1
  • §
    Win ratios were calculated using a non-parametric generalized pairwise comparison within subgroup strata; data are presented as point estimates and 95% CIs with two-sided interaction P values. No adjustments for multiple testing were made.1
  • CI=confidence interval; eGFR=estimated glomerular filtration rate; HF=heart failure; HFpEF=heart failure with preserved ejection fraction; HFrEF=heart failure with reduced ejection fraction; KCCQ-TSS=Kansas City Cardiomyopathy Questionnaire Total Symptom Score; LVEF=left ventricular ejection fraction; NYHA=New York Heart Association.

In the treatment of hospitalised patients with HFrEF and HFpEF after stabilisation*

JARDIANCE has a proven safety profile when initiated in hospital1

group-3@3x[1].jpg

  1. Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568-574. doi:10.1038/s41591-021-01659-1

  2. Anker SD, Butler J, Filippatos G, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N EnglJ Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038 (EMPEROR-Preserved results and the publication’s Supplementary Appendix.)

  3. Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190 (EMPEROR-Reduced results and the publication’s Supplementary Appendix.)

  • *
    Adult patients with chronic heart failure (NYHA class II, III, or IV) and reduced ejection fraction (LVEF ≤ 40%). 
    Adult patients with chronic heart failure (NYHA class II, III, or IV) and preserved ejection fraction (LVEF > 40%).2,3
  • AE=adverse event; HFpEF=heart failure with preserved ejection fraction; HFrEF=heart failure with reduced ejection fraction; LVEF=left ventricular ejection fraction; NYHA=New York Heart Association.

EMPULSE: Improvement in quality of life over 90-days 
Change from baseline in KCCQ-TSS*1

group-3@3x[1].jpg

  1. Kosiborod MN, Angermann CE, Collins SP, et al. Effects of empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure: results from the EMPULSE trial. Circulation. 2022;146(4):279-288.

  • CI=confidence interval; HF=heart failure.

In the treatment of hospitalised patients with HFrEF and HFpEF after stabilisation*

Hierarchical analysis confirmed clinical benefit for HF patients receiving JARDIANCE in hospital†1

group-3@3x[1].jpg

  1. Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568-574. doi:10.1038/s41591-021-01659-1

  2. Anker SD, Butler J, Filippatos G, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038 (EMPEROR-Preserved results and the publication’s Supplementary Appendix.)

  3. Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190 (EMPEROR-Reduced results and the publication’s Supplementary Appendix.)

  • *
    Adult patients with chronic heart failure (NYHA class II, III, or IV) and reduced ejection fraction (LVEF ≤ 40%).
  • Adult patients with chronic heart failure (NYHA class II, III, or IV) and preserved ejection fraction (LVEF > 40%). 2,3
  • †
    In the EMPULSE trial, a randomized, double-blind, placebo-controlled study of 530 patients with chronic heart failure regardless of LVEF, the efficacy and safety of JARDIANCE 10 mg (n=265) were evaluated vs placebo (n=265). The primary endpoint in the EMPULSE trial was clinical benefit, defined as a hierarchical composite of death from any cause, number of heart failure events and time to first heart failure event, or a 5 point or greater difference in change from baseline in the KCCQ-TSS at 90 days, as assessed using a win ratio. Patients treated with JARDIANCE experienced an overall clinical benefit 36% more likely than with placebo (win ratio 1.36; 95% CI: 1.09, 1.68; p=0.0054).1
  • ‡
    The stratified win ratio was calculated using a nonparametric generalized pairwise comparison within heart failure status strata; data are presented as the point estimate and 95% CI with a two sided P value. For the components of the win ratio, the percentages do not reflect randomized comparisons.1
  • §
    Heart failure events included heart failure hospitalizations, urgent heart failure visits and unplanned outpatient heart failure visits. An event was considered a heart failure event only if worsening signs and symptoms of heart failure were present and an intensification of therapy (defined as an increase of oral or IV diuretics, augmentation of a vasoactive agent, or starting a mechanical or surgical intervention) was performed.1
  • Both a reduction in all cause death and HFEs as well as an improvement in quality of life contributed to the increased number of wins in the empagliflozin group.1
  • CI=confidence interval; HF=heart failure; HFE=heart failure event; HFpEF=heart failure with preserved ejection fraction; HFrEF=heart failure with reduced ejection fraction; IV=intravenous; KCCQ-TSS=Kansas City Cardiomyopathy Questionnaire Total Symptom Score; LVEF=left ventricular ejection fraction; NYHA=New York Heart Association.

PC-IN-103696 Validity till Oct 2025